CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04140487
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:09.481215+00:00
Published At: 2026-04-16T00:00:00+00:00
Record Updated At: 2026-04-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Myelodysplastic/Myeloproliferative Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-16"
protocolSection.identificationModule.nctId: "NCT04140487"
protocolSection.identificationModule.officialTitle: "A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.